
Journal of Medicinal Chemistry p. 452 - 456 (1982)
Update date:2022-08-04
Topics:
Witiak, Donald T.
Brumbaugh, Richard J.
Heaslip, Richard J.
Rahwan, Ralf G.
Based upon findings that 2-n-propyl- and 2-n-butyl-3-(dimethylamino)-5,6-(methylenedioxy)indenes (1 and 2) inhibit a variety of calcium-activated cellular processes, it has previously been proposed that these compounds act as calcium antagonists with an intracellular site of action.In the present investigation, the diastereoisomeric dihydro analogues, cis- and trans-2-n-propyl- and cis- and trans-2-n-butyl-1-(dimethylamino)-5,6-(methylenedioxy)indans (5-8), and the trimethyl quaternary ammonium analogues of the unsaturated (3 and 4) and cis-saturated (9 and 10) systems were synthesized, and the ability of each to reverse norepinephrine- or KCl-induced contraction of the rat aorta was assessed.Saturation of 1 or 2 to produce the corresponding cis-aminoindan analogues (5 and 7) yielded compounds of similar spasmolytic activity, while saturation which yielded the respective trans forms (6 and 8) resulted in significant loss of potency.Methylation of either the cis unsaturated or saturated compounds to yield their respective quaternary derivatives also significantly reduced the potency of each compound.The reduced activity of the quaternary derivatives might be anticipated because of the limited cellular penetration of such compounds and is taken as evidence that the active tertiary analogues have an intracellular site of action.However, the results of the present investigation do not preclude the contribution of membrane effects to the pharmacological activity of the tertiary compounds (1, 2, 5, and 7), since the spasmolytically active analogues demonstrated a samewhat greater antagonistic potency against KCl-induced contractions as compared to their antagonism of the effects of norepinephrine.
View MoreContact:+86-731-84427351
Address:154 JIANXIANG SOUTH ROAD
Chengdu D-Innovation Pharmaceutical Co., Ltd
Contact:86-28-85105536
Address:1001, B6, No.88 Keyuan South Road, Chengdu Hi-Tech Zone
Shanghai Send Pharmaceutical Technology Co., Ltd.
website:http://www.shsendpharma.com
Contact:021-58088081, +8613585868794
Address::Room A601, Building 1,NO. 800 Qingdai Road Pudong District Shanghai,China
Chemvon Biotechnology Co. Ltd.
website:http://www.chemvon.com
Contact:86-21-58550039;86-21-31268550-8004
Address:Suite B-10#, 6999 Chuansha Road, Pudong District, Shanghai 201202, China
Xinjiang Fufeng Biotechnologies Co., Ltd.
Contact:+86-539-7287111
Address:GANQUANPU INDUSTRIAL PARK, ECONOMIC AND TECHNOLOGICAL DEVELOPMENT AREA (TOUTUNHE DISTRICT) OF URUMQI
Doi:10.1002/ardp.19893220809
(1989)Doi:10.1039/P19810003118
(1981)Doi:10.1016/j.ejmech.2004.07.010
(2004)Doi:10.1248/cpb.52.1153
(2004)Doi:10.1007/s11172-010-0280-3
(2010)Doi:10.1007/s11164-017-3023-3
(2017)